Novavax (NVAX) Trading Up 5.1%

Novavax, Inc. (NASDAQ:NVAX) traded up 5.1% during trading on Friday . The stock traded as high as $1.48 and last traded at $1.43. 6,553,064 shares were traded during mid-day trading, an increase of 10% from the average session volume of 5,968,580 shares. The stock had previously closed at $1.36.

Several equities research analysts have commented on the stock. BidaskClub lowered shares of Novavax from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Investment Research lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price objective on shares of Novavax in a research note on Wednesday, November 8th. Citigroup upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Tuesday, October 31st. Finally, Seaport Global Securities reiterated a “neutral” rating on shares of Novavax in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $3.12.

The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The company had revenue of $8.35 million during the quarter, compared to analyst estimates of $6.42 million. During the same quarter last year, the business posted ($0.24) EPS. Novavax’s quarterly revenue was up 158.5% compared to the same quarter last year. equities research analysts expect that Novavax, Inc. will post -0.62 EPS for the current year.

In related news, insider Stanley C. Erck purchased 100,000 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was bought at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the purchase, the insider now directly owns 228,279 shares in the company, valued at approximately $257,955.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.00% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in NVAX. Raymond James Financial Services Advisors Inc. grew its stake in Novavax by 49.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 29,800 shares in the last quarter. Profund Advisors LLC grew its stake in Novavax by 0.4% in the 2nd quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 455 shares in the last quarter. Voya Investment Management LLC grew its stake in Novavax by 18.6% in the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 21,639 shares in the last quarter. Brown Advisory Inc. grew its stake in Novavax by 74.8% in the 3rd quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 69,600 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new position in Novavax in the 2nd quarter valued at approximately $230,000. Institutional investors and hedge funds own 36.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/03/novavax-nvax-trading-up-5-1.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

What are top analysts saying about Novavax Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novavax Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit